BioSpace News Archive

Drug Development

Anthera Pharmaceuticals Announces Positive Outcome of Interim Futility Analysis in the Phase III RESULT Clinical Study of Sollpura

The study will proceed, as planned, with topline data expected in Q1 2018.

December 11, 2017
·
2 min read
Business

Distributed Bio and Boehringer Ingelheim Announce SuperHuman Platform Transfer

Distributed Bio announce an agreement with Boehringer Ingelheim to license the Distributed Bio SuperHuman Platform for accelerating biotherapeutics discovery across therapeutic areas.

December 11, 2017
·
2 min read
Policy

PharmaCyte Biotech Meets With Oncology Advisory Board

PharmaCyte Biotech announced that it recently met with its Oncology Advisory Board, which was formed to assist in optimizing and finalizing the clinical protocol and other clinical trial-related matters.

December 11, 2017
·
4 min read
Lone Star Bio

Astrotech Announces Results From Fiscal Year 2017 Annual Meeting of Shareholders

The Annual Meeting of Shareholders will reconvene on December 22, 2017.

December 11, 2017
·
3 min read
Genetown

Alnylam Announces Expansion of U.S. Orphan Drug Designation for Patisiran to Treatment of Transthyretin-Mediated Amyloidosis

Alnylam announced today the FDA has granted a request to amend the orphan drug designation for patisiran to the treatment of transthyretin-mediated amyloidosis (ATTR amyloidosis).

December 11, 2017
·
8 min read
Pharm Country

Biotech Investors and Leaders to Headline 10th Annual Biotech Showcase™ 2018

Understanding the health of the life sciences and biotech industries involves dissecting the past year’s successes.

December 11, 2017
·
6 min read
FDA

FDA Green Lights Intersect ENT’s SINUVA Sinus Implant

The implant is a new targeted approach to treating recurrent nasal polyp disease in patients who have had previous ethmoid sinus surgery.

December 11, 2017
·
7 min read
Business

Restoration Robotics Announces Appointment of Mark Hair as CFO

Mr. Hair brings with him over 20 years of executive management, financial advisory, consulting, and public company experience.

December 11, 2017
·
2 min read
Drug Development

TeneoBio’s Next Gen Multivalent anti-BCMAxCD3, TNB-383B, and Anti-BCMA UniDabs for CAR T-Cell Therapy of Multiple Myeloma Highlighted at the American Society of Hematology

Data showed results from the application of TeneoBio’s suite of technologies in the generation of the lead therapeutic candidate.

December 11, 2017
·
2 min read